<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10082">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975700</url>
  </required_header>
  <id_info>
    <org_study_id>PLX108-13</org_study_id>
    <nct_id>NCT02975700</nct_id>
  </id_info>
  <brief_title>A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma</brief_title>
  <official_title>A Phase I/II Open Label, Multicenter Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plexxikon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Plexxikon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase I/II study is to evaluate safety, pharmacokinetics, and
      preliminary efficacy of the investigational drug PLX3397 in subjects with unresectable or
      metastatic KIT-mutated melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (R2PD) [Part 1]</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of PLX3397, as measured by adverse events and serious adverse events [Part 1]</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of PLX3397 [Part 1]</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of PLX3397 [Part 1]</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peak concentration (Tmax) of PLX3397 [Part 1]</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life (t1/2) of PLX3397 [Part 1]</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR), which is the sum of complete response (CR) and partial response (PR) by RECIST 1.1 criteria [Part 2]</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum/plasma tumor biomarkers including CSF-1 [Part 1]</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response [Part 2]</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival [Part 2]</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival [Part 2]</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of PLX3397, as measured by adverse events and serious adverse events [Part 2]</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>PLX3397</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Open label, multicenter study includes a dose evaluation portion in which the safety profile of PLX3397 as a single oral agent will be evaluated
Part 2: An expansion cohort in which the efficacy and safety of PLX3397 administered at the recommended Phase 2 dose will be evaluated in patients with unresectable stage III or stage IV KIT-mutated melanoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLX3397</intervention_name>
    <arm_group_label>PLX3397</arm_group_label>
    <other_name>Pexidartinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Unresectable stage III or stage IV melanoma which is histologically confirmed at the
             treating institution with KIT mutation(s) not known to be resistant to PLX3397

          -  Presence of measurable lesions by Response Evaluation Criteria in Solid Tumors

          -  Eastern Cooperative Oncology Group (ECOG) performance Status (PS) 0-2

          -  Life expectancy ≥ 3 months

          -  Adequate organ and bone marrow function

          -  Women of child-bearing potential must have a negative serum pregnancy test at
             Screening and must agree to use an effective form of contraception from the time of
             the negative pregnancy test up to 3 months after the last dose of study drug. Women
             of non-child-bearing potential must have been postmenopausal for ≥ 1 year or
             surgically sterile.

          -  Fertile men must agree to use an effective method of birth control during the study
             and for up to 3 months after the last dose of study drug.

          -  Willingness and ability to provide written informed consent prior to any
             study-related procedures and to comply with all study requirements

        Exclusion Criteria:

          -  Prior treatment with a KIT inhibitor for melanoma

          -  Presence of NRAS or BRAF mutation

          -  Exposure to any investigational drug within 28 days or unresolved adverse effects
             from previous therapy

          -  Symptomatic brain metastases.

          -  Active secondary malignancy unless the malignancy is not expected to interfere with
             the evaluation of safety and is approved by the Sponsor

          -  Concomitant treatment with other anti-neoplastic agents (hormonal therapy acceptable)

          -  Uncontrolled intercurrent or infectious illness

          -  Major surgical procedure or significant traumatic injury within 14 days of initiating
             study drug or anticipation of the need for major surgery during the study

          -  Previous radiotherapy to 25% or more of the bone marrow and/or radiation therapy
             within 28 days prior to study entry

          -  Inability to swallow capsules, or refractory nausea and vomiting, malabsorption, an
             external biliary shunt, or significant bowel resection that would preclude adequate
             absorption

          -  Congestive heart failure (CHF) New York (NY) Heart Association class III or IV;
             unstable coronary artery disease (myocardial infarction [MI] more than 6 months prior
             to study entry is permitted); or serious cardiac arrhythmia

          -  Baseline QTcF ≥ 450 msec (for males) or ≥ 470 msec (for females) at Screening

          -  Active or chronic infection with human immunodeficiency virus (HIV), hepatitis C
             virus (HCV), or hepatitis B virus (HBV)

          -  Known chronic liver disease

          -  Women who are breast-feeding or pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Pelayo</last_name>
    <email>mpelayo@plexxikon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seodaemun-gu</city>
        <state>Seoul</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>South Korea</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>November 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PLX3397</keyword>
  <keyword>Kit-mutant Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
